NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

In a recent study posted to the bioRxiv* preprint server, researchers at the U.S National Institutes of Health demonstrated the efficacy of molnupiravir and nirmatrelvir, two oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals in the rhesus macaque model, the closest proxy to humans.